Market Overview

Morgan Stanley Maintains Overweight on Cimarex Energy, Raises Price Target to $124

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for XEC

DateFirmActionFromTo
Mar 2019Capital One FinancialDowngradesOverweightEqual-Weight
Feb 2019SusquehannaUpgradesNeutralPositive
Jan 2019MizuhoInitiates Coverage OnNeutral

View More Analyst Ratings for XEC
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (XEC)

The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Equillium's IPO: What You Need To Know